Results 51 to 60 of about 577,115 (171)

The ErbB2 receptor and breast carcinoma cell migration : memo is a novel mediator of cell motility [PDF]

, 2003
The ErbB family of receptor tyrosine kinases play important role in normal physiological processes occurring during development; moreover, their deregulated expression has been implicated in human cancer. Cancer patients, whose tumors have alterations in
Marone, Romina
core   +1 more source

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer

Cell Death and Disease, 2022
Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2.
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo   +18 more
doaj   +1 more source

Combinatorial strategy using protein kinase inhibitors and a cytotoxic compound for highly resistant glioblastoma cells : "in vitro studies" [PDF]

, 2007
Glioblastoma multiforme (GBM) is the most frequent and the most aggesssive malignant neoplasm of the human central nervous system (CNS), with a median survival of less than one year. These neoplasms are radio- and chemo-resistant, and are highly invasive,
Failly, Mike
core   +1 more source

Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. [PDF]

PLoS ONE, 2012
Growth factors activating the ErbB receptors have been described in prostate tumors. The androgen dependent prostate cancer cell line, LNCaP, expresses the ErbB-1, ErbB-2 and ErbB-3 receptor tyrosine kinases.
Eran Schmukler, Ben Shai, Marcelo Ehrlich, Ronit Pinkas-Kramarski   +3 more
doaj   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report

Journal of International Medical Research, 2020
The ErbB family is composed of four cell membrane receptors: ErbB-1 (epidermal growth factor receptor or human epidermal growth factor receptor [HER]1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4).
Mengyao Sun, Ye Guo, Xu Wang, Chao Sun, Jiangbo Shao, Yinghui Xu, Shi Qiu, Kewei Ma   +7 more
doaj   +1 more source

Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors

Cell Reports Medicine, 2021
Summary: Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR binding. Tumor selectivity is crucial because on-
Paris Kosti, James W. Opzoomer, Karen I. Larios-Martinez, Rhonda Henley-Smith, Cheryl L. Scudamore, Mary Okesola, Mustafa Y.M. Taher, David M. Davies, Tamara Muliaditan, Daniel Larcombe-Young, Natalie Woodman, Cheryl E. Gillett, Selvam Thavaraj, John Maher, James N. Arnold   +14 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

A Peptide Antagonist of the ErbB1 Receptor Inhibits Receptor Activation, Tumor Cell Growth and Migration In Vitro and Xenograft Tumor Growth In Vivo

Cellular Oncology, 2010
The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in tumorigenesis and cancer disease progression, and therefore has become an attractive target for structure-based drug design.
Ruodan Xu, Gro Klitgaard Povlsen, Vladislav Soroka, Elisabeth Bock, Vladimir Berezin   +4 more
doaj   +1 more source